# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k071711   
B. Purpose for Submission: Addition of sample matrix (serum) to a cleared device   
C. Measurand: Anti- Saccharomyces Cerevisiae Antibody (ASCA)   
D. Type of Test: Qualitative ELISA   
E. Applicant: TECHLAB®   
F. Proprietary and Established Names: ASCA-CHEK   
G. Regulatory Information: 1. Regulation section: 21 CFR 866.5785, Anti-Saccharomyces Cerevisiae (ASCA) test system 2. Classification: II 3. Product code: NBT, Antibodies, Saccharomyces Cerevisiae (S. Cerevisiae) 4. Panel: Immunology 82

# H. Intended Use:

1. Intended use(s): The ASCA-CHEK test is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human anti-S. cerevisiae antibodies (ASCA) in feces and serum. The test result is used as an aid in the diagnosis of Crohn’s disease in combination with clinical and other laboratory findings. FOR IN VITRO DIAGNOSTIC USE.   
2. Indication(s) for use: Same as intended use.   
3. Special conditions for use statement(s): The devices are for prescription use only.   
4. Special instrument requirements: Microplate reader capable of measuring optical density (OD) at $4 5 0 \mathrm { n m }$ or $4 5 0 / 6 2 0 \mathrm { n m }$ .

# I. Device Description:

Each device contains the following: microplate strips with breakaway microwells (12 strips $_ { \textrm { X 8 } }$ wells/strip) coated with antigens of Saccharomyces cerevisiae; goat antihuman polyclonal immunoglobulin-horse radish peroxidase conjugate; positive control; wash buffer 20X concentrate; diluent 10X concentrate; tetramethylbenzidine and peroxide substrate; 0.6N Sulfuric acid stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Quanta Lite™ ASCA (S. Cerevisiae) IgG ELISA

2. Predicate K number(s): k000732

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ASCA-CHEK</td><td rowspan=1 colspan=1>Quanta LiteTM ASCA IgGELISA</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>To aid in the diagnosis of Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>OD reading</td><td rowspan=1 colspan=1>450 nm or 450/620nm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>96 well microtiter plates</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Semi-quantitative</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="1" rowspan="1">Purified antigen fromSaccharomyces cerevisiae</td><td colspan="1" rowspan="1">Partially purified anddisrupted S. cerevisiaeantigen</td></tr><tr><td colspan="1" rowspan="1">Enzyme-Conjugate</td><td colspan="1" rowspan="1">HRP goat anti-human polyclonalimmunoglobulin conjugate</td><td colspan="1" rowspan="1">HRP goat anti-human IgGconjugate</td></tr><tr><td colspan="1" rowspan="1">Incubation times</td><td colspan="1" rowspan="1">30-30-15</td><td colspan="1" rowspan="1">30-30-30</td></tr><tr><td colspan="1" rowspan="1">Positive control</td><td colspan="1" rowspan="1">Ready to use Positive Sera</td><td colspan="1" rowspan="1">Prediluted: ASCA IgG Lowand High Positive Sera</td></tr><tr><td colspan="1" rowspan="1">Negative control</td><td colspan="1" rowspan="1">1X Diluent</td><td colspan="1" rowspan="1">Prediluted Negative Serum</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Feces and Serum</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Sample dilutionand sample volumerequired</td><td colspan="1" rowspan="1">1:1000 dilution with sample diluent</td><td colspan="1" rowspan="1">1:101 dilution of 5 μLserum with 500 μL HRPSample Diluent</td></tr><tr><td colspan="1" rowspan="1">Sample diluent</td><td colspan="1" rowspan="1">10X Phosphate Buffered Proteinsolution with 0.2% thimerosal</td><td colspan="1" rowspan="1">Tris-buffered saline,Tween-20, proteinstabilizer and preservative</td></tr><tr><td colspan="1" rowspan="1">Wash bufferconcentrate</td><td colspan="1" rowspan="1">20X Phosphate-buffered saline,detergent, and 0.2% thimerosal</td><td colspan="1" rowspan="1">40X Tris-buffered salineand Tween 20</td></tr><tr><td colspan="1" rowspan="1">Stop solution</td><td colspan="1" rowspan="1">0.6N sulphuric acid</td><td colspan="1" rowspan="1">0.344M sulphuric acid</td></tr><tr><td colspan="1" rowspan="1">Washing procedureand number ofwashes</td><td colspan="1" rowspan="1">Manual wash using a Squirt bottlewith fine- tipped nozzle with ~400μL of 1X Wash Solution; total offour washes</td><td colspan="1" rowspan="1">Microplate washing device(200-300 μL of dilutedHRP wash buffer using arepeating, or multichannelpipette, or automatedsystem); total of threewashes</td></tr><tr><td colspan="1" rowspan="1">OD measurement</td><td colspan="1" rowspan="1">Within 2-10 minutes</td><td colspan="1" rowspan="1">Within one hour</td></tr><tr><td colspan="1" rowspan="1">ASCA Results</td><td colspan="1" rowspan="1">(1) 450 nm wavelength: (single</td><td colspan="1" rowspan="1">Results in Units:</td></tr><tr><td rowspan="4">Interpretation</td><td>wavelength spectrophotometer)</td><td>Negative: 0.0-20.0</td></tr><tr><td>Negative: OD450 &lt; 0.110 Positive: OD450 ≥ 0.110</td><td>Equivocal: 20.1-24.9 Positive: ≥ 25.0</td></tr><tr><td></td><td></td></tr><tr><td>(2) 450/620 nm wavelength: (dual wavelength spectrophotometer) Negative: : OD450/620 &lt; 0.080</td><td></td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP7-A Interference Testing in Clinical Chemistry

# L. Test Principle:

The microwells are pre-coated with immobilized antigens of Saccharomyces cerevisiae. An aliquot of either serum or fecal specimen is emulsified in the diluent. The diluted specimen, the ready to use positive control, and the 1X diluent negative control are transferred to the microwell. If ASCA are present in the specimen, they will bind to the immobilized antigens. After incubation, the wells are washed and the conjugate added. The conjugate binds to the ASCA captured by the immobilized antigens. A second series of wash steps remove any unbound material. Following the addition of the substrate, a color is detected spectrophotometrically due to the enzyme-antibody-antigen complexes that form the presence of ASCA.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Precision testing was done on a single wavelength spectrophotometer $\mathrm { ( O D _ { 4 5 0 } ) }$ ). The intra-assay reproducibility was determined by testing 8 human serum specimens (4 ASCA positive and 4 ASCA negative) 8 times in the same run. The positive samples comprised of samples with varying concentrations of ASCA. For the analysis, each serum was diluted 1:1000 with the kit diluent. The OD data were reformatted to reflect the reportable result of the assay, which would either be positive or negative. The table below summarizes the OD output as well as the final call for each of the replicates.

<table><tr><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>Test 1OD450</td><td rowspan=1 colspan=1>Test 2OD450</td><td rowspan=1 colspan=1>Test 3OD450</td><td rowspan=1 colspan=1>Test 4OD450</td><td rowspan=1 colspan=1>Test 5OD450</td><td rowspan=1 colspan=1>Test 6OD450</td><td rowspan=1 colspan=1>Test 7OD450</td><td rowspan=1 colspan=1>Test 8OD450</td><td rowspan=1 colspan=1>Final Call foreach replicate</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.281</td><td rowspan=1 colspan=1>0.253</td><td rowspan=1 colspan=1>0.280</td><td rowspan=1 colspan=1>0.283</td><td rowspan=1 colspan=1>0.306</td><td rowspan=1 colspan=1>0.318</td><td rowspan=1 colspan=1>0.273</td><td rowspan=1 colspan=1>0.274</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0.287</td><td rowspan=1 colspan=1>0.277</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>0.295</td><td rowspan=1 colspan=1>0.232</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>0.264</td><td rowspan=1 colspan=1>0.242</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.136</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>0.117</td><td rowspan=1 colspan=1>0.125</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>0.118</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.155</td><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>0.125</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>Negative</td></tr></table>

The inter-assay precision was determined by testing 4 ASCA Ig- positive and 4 ASCA Ig-negative serum specimens eight times over a two-day period using a single lot of the ASCA-CHEK test. Results are summarized below.

<table><tr><td rowspan=1 colspan=1>#</td><td rowspan=1 colspan=1>Test 1OD450</td><td rowspan=1 colspan=1>Test 2OD450</td><td rowspan=1 colspan=1>Test 3OD450</td><td rowspan=1 colspan=1>Test 4OD450</td><td rowspan=1 colspan=1>Test 5OD450</td><td rowspan=1 colspan=1>Test 6OD450</td><td rowspan=1 colspan=1>Test 7OD450</td><td rowspan=1 colspan=1>Test 8OD450</td><td rowspan=1 colspan=1>Final call for eachreplicate</td></tr><tr><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0.293</td><td rowspan=1 colspan=1>0.277</td><td rowspan=1 colspan=1>0.178</td><td rowspan=1 colspan=1>0.240</td><td rowspan=1 colspan=1>0.256</td><td rowspan=1 colspan=1>0.365</td><td rowspan=1 colspan=1>0.316</td><td rowspan=1 colspan=1>0.282</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0.268</td><td rowspan=1 colspan=1>0.253</td><td rowspan=1 colspan=1>0.198</td><td rowspan=1 colspan=1>0.269</td><td rowspan=1 colspan=1>0.253</td><td rowspan=1 colspan=1>0.366</td><td rowspan=1 colspan=1>0.260</td><td rowspan=1 colspan=1>0.299</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.134</td><td rowspan=1 colspan=1>0.164</td><td rowspan=1 colspan=1>0.163</td><td rowspan=1 colspan=1>0.126</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>0.143</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0.159</td><td rowspan=1 colspan=1>0.189</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>0.186</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>0.135</td><td rowspan=1 colspan=1>0.142</td><td rowspan=1 colspan=1>0.168</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.088</td><td rowspan=1 colspan=1>Negative</td></tr></table>

b. Linearity/assay reportable range: Not applicable.

Sample dilution

The specimen dilution of 1:1000 was optimized using titrations (1:100 to 1:1000) of known ASCA-positive and ASCA-negative serum specimens. The 1:1000 dilution was then challenged using healthy control serum panel and clinical specimens using 3 different $\mathrm { O D } _ { 4 5 0 \mathrm { n m } }$ cut-offs (0.110, 0.120 and 0.150). The dilution and $\mathrm { O D } _ { 4 5 0 \mathrm { n m } }$ cut-off (1:1000 and ${ \ge } 0 . 1 1 0 $ ) that provided the highest range of correlations to Crohn’s disease was considered optimal. This was further challenged in the clinical evaluations.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): There is no recognized standard or reference material for ASCA. The calibrator and positive control (confirmed ASCA positive) were prepared inhouse and the designated O.D. was assigned during development process.

d. Detection limit: Not applicable.

e. Analytical specificity:

Interference: Interference studies were performed as follows: Control samples shown below were divided into two aliquots. One aliquot was mixed with equal volumes of high ASCA-Ig-positive serum samples. The other aliquot was mixed with equal volumes of ASCA Ig-negative samples. All samples were tested seven times using ASCA CHEK. All ASCA-Ig-positive samples remained positive and all ASCA Ig-negative samples remained negative. No interference was observed.

<table><tr><td rowspan=1 colspan=1>Test Substance</td><td rowspan=1 colspan=1>Method of Analysis</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>Hitachi 917</td><td rowspan=1 colspan=1>&gt;20 U/L</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>Olympus AU 5000</td><td rowspan=1 colspan=1>504 mg/dL</td></tr><tr><td rowspan=1 colspan=1>RF</td><td rowspan=1 colspan=1>Nephelometry</td><td rowspan=1 colspan=1>27.9 IU/mL</td></tr><tr><td rowspan=1 colspan=1>ANA</td><td rowspan=1 colspan=1>Nephelometry</td><td rowspan=1 colspan=1>0.263 ratio</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (free)</td><td rowspan=1 colspan=1>Beckman LX20</td><td rowspan=1 colspan=1>19 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>Beckman LX20</td><td rowspan=1 colspan=1>18 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolyzed blood</td><td rowspan=1 colspan=1>Visual red color</td><td rowspan=1 colspan=1>Hemolyzed</td></tr></table>

# Cross-reactivity:

Sera from non-Crohn’s disease were tested in the ASCA-CHEK test and showed a positivity range of $4 \%$ to $1 3 \%$ .

<table><tr><td rowspan=1 colspan=1>Non-Crohn&#x27;s diseasegroup</td><td rowspan=1 colspan=1>Numbertested</td><td rowspan=1 colspan=1>Numberpositive</td><td rowspan=1 colspan=1>%Positive</td></tr><tr><td rowspan=1 colspan=1>Ulcerative colitis</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>13%</td></tr><tr><td rowspan=1 colspan=1>Irritable bowel syndrome</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>Constipation</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Esophagitis</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>H.pylori</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Alcoholic cirrhosis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5%</td></tr><tr><td rowspan=1 colspan=1>ANA-positive</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Healthy</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4%</td></tr></table>

Distribution of ASCA reactivity in patients with autoimmune liver disease and inflammatory bowel disorders shown in the table below is from a publication by Muratori P, Muratori L, et.al.(Clin Exp Immunol 2003;132:473-476).

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>No. ofpatients</td><td rowspan=1 colspan=1>ASCA</td><td rowspan=1 colspan=1>ASCAIgA</td><td rowspan=1 colspan=1>ASCAIgG</td><td rowspan=1 colspan=1>ASCAIgA + IgG</td></tr><tr><td rowspan=1 colspan=1>AMA-pos. PBC</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>19 (18)</td><td rowspan=1 colspan=1>17 (16)</td><td rowspan=1 colspan=1>7(7)</td><td rowspan=1 colspan=1>4(4)</td></tr><tr><td rowspan=1 colspan=1>AMA-neg. PBC</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>9 (53)</td><td rowspan=1 colspan=1>6 (35)</td><td rowspan=1 colspan=1>6 (35)</td><td rowspan=1 colspan=1>3 (18)</td></tr><tr><td rowspan=1 colspan=1>Type 1 AIH</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>8 (27)</td><td rowspan=1 colspan=1>6 (20)</td><td rowspan=1 colspan=1>7(23)</td><td rowspan=1 colspan=1>5(17)</td></tr><tr><td rowspan=1 colspan=1>Type 2 AIH</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>4(11)</td><td rowspan=1 colspan=1>2(5)</td><td rowspan=1 colspan=1>4(11)</td><td rowspan=1 colspan=1>2(5)</td></tr><tr><td rowspan=1 colspan=1>PSC</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>11 (44)</td><td rowspan=1 colspan=1>8 (32)</td><td rowspan=1 colspan=1>7 (28)</td><td rowspan=1 colspan=1>4 (16)</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;s disease</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>16 (70)</td><td rowspan=1 colspan=1>12 (52)</td><td rowspan=1 colspan=1>16 (70)</td><td rowspan=1 colspan=1>12 (52)</td></tr><tr><td rowspan=1 colspan=1>Ulcerative colitis</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>9 (36)</td><td rowspan=1 colspan=1>5 (20)</td><td rowspan=1 colspan=1>7 (28)</td><td rowspan=1 colspan=1>5 (20)</td></tr><tr><td rowspan=1 colspan=1>Blood donors</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1(5)</td><td rowspan=1 colspan=1>1(5)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=6>AMAMA, antimitochondrial antibody; PBC, primary biliary cirrhosis; AIH,autoimmune hepatitis;PS PSC, primary sclerosing cholangitis.</td></tr></table>

# f. Assay cut-off:

Two hundred and fifty-seven (257) serum specimens (172 Crohn’s disease and 85 non-Crohn’s disease) were used to determine the optimal OD cut-off for a positive result. $\mathrm { O D } _ { 4 5 0 }$ (single wavelength spectrophotometer) cut-offs at $2 0 . 1 1 0$ , 0.120 and 0.150 and $\mathrm { O D } _ { 4 5 0 / 6 2 0 }$ (dual wavelength spectrophotometer) at $2 0 . 0 8 0$ and 0.110 were evaluated.

Specimens were diluted at 1:1000 and tested by the ASCA-CHEK test for ASCA Ig. The optimal cut-off that provided the best correlation to clinically confirmed Crohn’s disease was determined. The OD cut-off of $2 0 . 1 1 0$ at $\mathrm { O D } _ { 4 5 0 }$ and $2 0 . 0 8 0$ at $\mathrm { O D } _ { 4 5 0 / 6 2 0 }$ provided the largest number of samples that correlated to Crohn’s disease. The following table shows the results for the ASCA-CHEK test. The number of Crohn’s and non-Crohn’s samples above and below each OD cutoff was determined.

<table><tr><td rowspan=1 colspan=8>OD450</td></tr><tr><td rowspan=2 colspan=1>Site</td><td rowspan=2 colspan=1>OD</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>Crohn&#x27;s samples</td><td rowspan=1 colspan=2>Non-Crohn&#x27;s samples</td></tr><tr><td rowspan=1 colspan=2>above cut-off</td><td rowspan=1 colspan=1>below cut-off</td><td rowspan=1 colspan=1>above cut-off</td><td rowspan=1 colspan=1>below cut-off</td></tr><tr><td rowspan=3 colspan=1>Children&#x27;s Hospitalof Harvard</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=2>49</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>0.120</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=2>41</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=2>35</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=3 colspan=1>Riley Hospital</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=2>12</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.120</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=2>11</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=2>8</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>Mayo clinic</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=2>34</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.120</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=2>32</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=2>30</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=8>OD450/620</td></tr><tr><td rowspan=2 colspan=1>Kliniken Essen-Mitte</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=2>14</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=2>19</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3</td></tr></table>

# 2. Comparison studies:

a. Method comparison with predicate device: A total of 180 (163 Inflammatory Bowel Disease, 17 Irritable Bowel Syndrome/non-IBD) patients were enrolled at 3 clinical sites. Each patient was assessed for active inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). In addition, each patient was diagnosed using in-house procedures and a single serum specimen was collected for analysis with the ASCA-CHEK test. For clinical sites #1 – 3, serum specimens were frozen and sent to TECHLAB $^ \mathrm { \textregistered }$ , Inc. for analysis for ASCA Ig. Site 1 and site 2 tested only pediatric samples. The following results were obtained:

Pediatric samples: Site #1 (Children’s Hospital of Harvard Medical School) (frozen sera)   

<table><tr><td rowspan=2 colspan=2>N = 94</td><td rowspan=1 colspan=3>QuantaLite ASCA IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>94</td></tr></table>

Positive percent agreement $= 8 0 \%$ $( 9 5 \% C \mathrm { I } 6 4  – 9 0 \% )$

# Negative percent agreement $= 7 4 \%$ $9 5 \% C \mathrm { I } 5 9 { - } 8 5 \% )$ Overall percent agreement $= 7 7 \%$ $9 5 \% C \mathrm { I } 6 8 { - } 8 6 \% )$

Site #2 Riley’s Children’s Hospital (frozen sera)   

<table><tr><td rowspan=2 colspan=2>N = 23</td><td rowspan=1 colspan=3>QuantaLite ASCA IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>23</td></tr></table>

Positive percent agreement $= 9 0 \%$ $( 9 5 \% C \mathrm { I } 5 4 \ – 1 0 0 \% )$ Negative percent agreement $= 7 7 \%$ $9 5 \% C \mathrm { I } 4 6 { - } 9 4 \% )$ Overall percent agreement $= 8 3 \%$ $( 9 5 \% C \mathrm { I } 6 4 \ – 9 3 \% )$

Adult samples: Site #3 Mayo Clinic (frozen sera)

<table><tr><td rowspan=2 colspan=2>N = 63</td><td rowspan=1 colspan=3>QuantaLite ASCA IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>63</td></tr></table>

Positive percent agreement $= 7 9 \%$ $9 5 \% C 1 6 2 – 9 0 \%$ Negative percent agreement $= 8 4 \%$ $9 5 \% C \mathrm { I } 6 3  – 9 5 \% )$ Overall percent agreement $= 8 1 \%$ $( 9 5 \% C \mathrm { I } 7 0  – 8 8 \% )$

Since frozen samples were used in the comparison studies, the sponsor evaluated the effect of a single freeze-thaw cycle on test results in the serum ASCA-CHEK test. For the analysis, 9 ASCA Ig-positive serum samples and 5 ASCA Ig-negative serum samples were tested. An aliquot from each sample was removed and frozen at $- 2 0 ^ { \circ } \mathrm { C }$ followed by a single thaw at room temperature on the day of analysis. The test results for the frozen and unfrozen specimens showed all negative samples remained negative and all positive samples remained positive at all time periods.

b. Matrix comparison: Serum is the only matrix tested in this submission.

3. Clinical studies:

a. Clinical Sensitivity/ Clinical specificity: The same samples used in method comparison were used to assess sensitivity and specificity. In addition, 77 samples from adult patients were tested on Site 4 (Kliniken Essen-Mitte) for clinical assessment. The following results were obtained:

Site #1 (Children’s Hospital of Harvard Medical School) False positive samples were from patients with ulcerative colitis. Sera from non-Crohn’s disease tested in the ASCA-CHEK test showed a positivity range of $4 \%$ to $1 3 \%$ . This accounts for a lower specificity for this site.

<table><tr><td rowspan=2 colspan=2>N = 94 Pediatricsamples</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>94</td></tr></table>

Sensitivity $= 6 0 \%$ $( 9 5 \% C \mathrm { I } 4 8  – 7 1 \% )$ Specificity $= 7 7 \%$ (95%CI 54-91%)

Site #2 (Riley’s Children’s Hospital)   

<table><tr><td rowspan=2 colspan=2>N = 23 Pediatricsamples</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23</td></tr></table>

Sensitivity $= 6 0 \%$ $9 5 \% C 1 3 6 { - } 8 0 \% )$ Specificity $= 1 0 0 \%$

Site #3 (Mayo Clinic)

<table><tr><td rowspan=2 colspan=2>N = 63 Adultsamples</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>63</td></tr></table>

Sensitivity $= 7 1 \%$ $9 5 \% C 1 5 6 { - } 8 3 \% )$ Specificity $= 1 0 0 \%$

Site #4 (Kliniken Essen-Mitte)

<table><tr><td rowspan=2 colspan=2>N = 77 Adultsamples</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>77</td></tr></table>

# Sensitivity $= 5 6 \%$ $( 9 5 \% C \mathrm { I } 3 8  – 7 3 \% )$ Specificity $= 9 1 \%$ $( 9 5 \% C I 7 8  – 9 7 \% )$

The combined test results for both pediatric study sites to clinical assessments for disease diagnosis including non-IBD healthy controls is shown below.

<table><tr><td rowspan=2 colspan=2>N = 136</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>61</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>136</td></tr></table>

Sensitivity $= 6 0 \%$ $( 9 5 \% C \mathrm { I } 4 9 - 7 0 \% )$ Specificity $= 8 6 \%$ $( 9 5 \% C \mathrm { I } 5 8  – 7 6 \% )$

The combined test results for both adult study sites to clinical assessments for disease diagnosis including non-IBD healthy controls is shown below.

<table><tr><td rowspan=2 colspan=2>N=215</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>59</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>156</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>215</td></tr></table>

Sensitivity $= 6 5 \%$ $( 9 5 \% C 1 5 3  – 7 5 \% )$ Specificity $= 9 5 \%$ $( 9 5 \% C \mathrm { I } 8 9  – 9 8 \% )$

The combined test results for all 4 study sites including samples from 94 healthy persons showed the following:

<table><tr><td rowspan=2 colspan=2>N = 351</td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;sdisease</td><td rowspan=1 colspan=1>Ulcerativecolitis and non-IBD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>ASCACheck</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>231</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>172</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>351</td></tr></table>

Sensitivity $= 6 2 \%$ $( 9 5 \% C \mathrm { I } 5 5  – 6 9 \% )$ . Specificity $= 9 3 \%$ $( 9 5 \% C \mathrm { I } 8 8  – 9 6 \% )$

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Same as assay cut-off

5. Expected values/Reference range: Expected value in normal population is negative. Of the 94 healthy persons tested, $4 \%$ tested positive for ASCA.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.